Efektivitas Rifapentine Pada Pasien Dewasa Dengan Infeksi TuberkulosisLaten (ITBL): Sebuah Kajian Sistematis

Tuberculosis (TB) is an infectious disease whose successful treatment in Indonesia is affected by malnutrition, smoking, diabetes mellitus, and HIV infection. People with good immunity can prevent developing active disease, but the bacteria persistent in a dormant state. It will be active tuberculosis whenever (in few months) the immune system unable controlling the growth of TB bacteria. This systematic review aims to examine the effectiveness of rifapentine and its use with other regimens in patients with latent tuberculosis infection (LTBI). This study included literature published in the PubMed database from early January 2011 to January 2021, with keywords: "Effectiveness Rifapentine", “Tuberculosis”, and the Boolean operators, "AND". This study reported that there wew seventheen in studies countries, none in Indonesia. This study come to end that a regiment therapy with a combination of Rifapentine (P) and Isoniazid (H) once-weekly dose (called 3HP) for three months shows a good efficacy in LTBI patients, can improve patient adherence because of a shorter regiment administration and reduce the hepatotoxicity risk in patients with a history of chronic liver disease or increased aspartate transaminase (AST) level.